Oral FGFR1-3 Inhibitor Boosted Height Velocity in Common Genetic Growth Disorder

Source Summary

(MedPage Today) -- Treatment with a once-daily FGFR1-3 tyrosine kinase inhibitor led to significant increases in growth among children with achondroplasia, the phase III PROPEL 3 study showed. The least-squares mean change from baseline in the...